EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

United Therapeutics Corporation (U2TH34) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of United Therapeutics Corporation BRL 141, price BRL 142, upside -0.7%, quality 73 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · BR · ISIN US91307C1027

UT Broad data Sep 29, 2026

United Therapeutics Corporation

U2TH34 · SA

NeutralThe stock looks roughly fairly valued with average quality.

·Fair value R$141.00 · Fairly valued (−0.7%)
✓Quality 73/100
✓Healthy Growth (revenue 3y +18.0 %/yr)
✓Highly profitable · 40.6% net margin (TTM)
✓Low debt · generates free cash flow
✓Wide moat 83/100

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

R$153.67 R$54.20 Fair Value R$141.00 Jul 2023 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 29, 2026.

How to read this chart

38‑month range R$54.20 – R$153.67 · fair‑value band R$88.85 – R$222.82 · the R$142.05 price screens above the R$141.00 fair value. Dashed = 300-day average. As of Sep 29, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.

Show more

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.

Stock analysis

United Therapeutics Corporation (U2TH34) currently trades at R$142.05, while our model-based Fair Value estimate is R$141.00, so the stock looks roughly fairly valued today (gap 0.7%).

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of R$194.67 per share, and 11 of the 24 models we run sit above the R$142.05 price.

Bear case: the Asset-Based group reads lowest at R$29.25, and 13 of the 24 models stay below the price. Evidence for this calculation is high.

Scenario range: R$88.85 (bear) to R$222.82 (bull), the price of R$142.05 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 73/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

United Therapeutics Corporation reported revenue of $3.2B in FY2025 versus $1.7B in FY2021, a compound +17.2%/yr. Reported net income was $1.3B in FY2025, compounding +29.4%/yr from FY2021.

Key figures

Market cap R$113B (≈ $21.6B) · P/E ratio 20.3 · P/S ratio 8.50 · EPS (TTM) R$7.01 · Net margin 41.9% · Return on equity 20.3% · Return on assets (EBIT) 16.2% · Operating margin 41.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 51 out of 100 (low confidence).

What moves the price

The share trades about 8% below its 52-week high and 25% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −1%, U2TH34 screens cheaper than that median.

Fair Value models

Bear R$88.85 Fair Value R$141.00 Bull R$222.82
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (R$5.30 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF R$101.97 R$180.74 R$379.40 72
Growth DCF R$99.44 R$192.24 R$339.17 72
EPV R$78.66 R$90.17 R$100.24 71
All 24 models by family
DCF Models
FCF DCF R$101.97 R$180.74 R$379.40 72
Owner Earnings R$89.58 R$173.00 R$333.53 69
5Y Revenue Exit R$54.87 R$83.13 R$120.97 69
5Y EBITDA Exit R$100.34 R$184.12 R$295.11 70
5Y P/E Exit R$123.44 R$235.44 R$372.47 66
10Y Revenue Exit R$68.29 R$102.18 R$154.70 63
10Y EBITDA Exit R$100.32 R$179.48 R$311.63 63
10Y P/E Exit R$116.13 R$218.76 R$381.35 59
Earnings-Based
Graham-Dodd R$55.83 R$327.55 R$456.00 61
Lynch FV R$92.82 R$132.60 R$172.38 58
PEG = 1.0 R$92.82 R$132.60 R$172.38 55
EPV R$78.66 R$90.17 R$100.24 71
Multiples
P/E Multiple R$129.32 R$172.42 R$215.53 63
P/S Multiple R$29.37 R$39.16 R$48.95 58
P/B Multiple R$104.68 R$139.58 R$174.47 55
EV/EBIT R$126.64 R$165.66 R$204.68 66
EV/EBITDA R$104.23 R$135.78 R$167.33 67
EV/Revenue R$34.25 R$44.82 R$55.39 54
Asset-Based
NCAV (Graham) R$21.83 R$29.25 R$43.65 54
Growth DCF
Growth DCF R$99.44 R$192.24 R$339.17 72
Rev-Margin DCF R$54.87 R$83.02 R$122.26 69
Economic Profit
Residual Income R$53.62 R$71.96 R$126.84 64
ROIC Compounder R$92.60 R$127.71 R$176.57 68
Growth Earnings
Growth-Adj P/E R$136.27 R$194.67 R$253.08 65

Open the full fair value analysis →

Notify me when U2TH34 reaches fair value

Put U2TH34 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 73/100

Of which business quality 73 · Market factors (momentum, volatility) 67

Profitability 70
Margins and returns on capital today
Quality Growth 51
Are margins and returns improving?
Cashflow 74
Earnings quality: real cash, not paper profit
Fin. Strength 93
Balance sheet, leverage, solvency risk
Investment 35
Disciplined investing over empire-building
Low Volatility 84
Calm price path (market factor)
Momentum 52
Price trend over the last 3–12 months (market factor)
52W Momentum 72
Distance to the 52-week high (market factor)
Net Issuance 100
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+10.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.0%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+23.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+23.7%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.33% → 47%

Watch U2TH34, get fair value alerts →

Compare United Therapeutics Corporation with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Merck KGaA MRK €134.45 €108.94 −19%
Takeda Pharmaceutical Company TAK $18.90 $11.45 −39%
Teva Pharmaceutical Industries Limited TEVA $39.31 $20.88 −47%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,852 ₹1,979 +7%
Galderma Group GALD CHF 163.00 CHF 110.32 −32%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥44.86 ¥49.35 +10%
Haleon plc HLN $9.26 $8.49 −8%
Sandoz Group SDZ CHF 71.16 CHF 40.32 −43%
Zoetis Inc ZTS $70.30 $110.50 +57%
Divi's Laboratories Limited DIVISLAB ₹9,620 ₹1,871 −81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

United Therapeutics Corporation · Fair Value
R$141.00 −1%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "United Therapeutics Corporation Fair Value". https://www.fairvalue-calculator.com/stock/U2TH34

Frequently asked questions

Is United Therapeutics Corporation (U2TH34) overvalued or undervalued?
As of Sep 29, 2026, our model estimates a fair value of R$141.00 versus a price of R$142.05, about −1% upside (fairly valued).
What is the fair value of U2TH34?
Our model-based fair value for United Therapeutics Corporation is R$141.00 (as of Sep 29, 2026), built from audited fundamentals. The current price: R$142.05.
What is the quality score of U2TH34?
United Therapeutics Corporation has a Quality Score of 73/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for United Therapeutics Corporation (U2TH34)?
Our model-based price target is the fair value of R$141.00 (as of Sep 29, 2026) from 24 valuation models. Cautious scenario R$88.85, optimistic scenario R$222.82. It is a calculation from audited fundamentals, not an analyst target.
What is the United Therapeutics Corporation stock forecast for 2026?
Our models put fair value at R$141.00, about −1% upside versus a price of R$142.05 (fairly valued). Cautious scenario R$88.85, optimistic scenario R$222.82. The calculation is refreshed regularly with new filings.
What is the revenue of United Therapeutics Corporation (U2TH34)?
United Therapeutics Corporation reported trailing-twelve-month revenue of about $3.2B (latest available figure, as of Sep 29, 2026).
What is the intrinsic value of United Therapeutics Corporation (U2TH34)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For United Therapeutics Corporation it is R$141.00 per share (as of Sep 29, 2026), against a price of R$142.05. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is United Therapeutics Corporation stock overvalued or undervalued in 2026?
As of Sep 29, 2026, U2TH34 trades above its calculated fair value: price R$142.05, fair value R$141.00, a gap of about −1% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of U2TH34?
No. The price is what the market pays today (R$142.05); the fair value is what the company's own numbers justify (R$141.00). For United Therapeutics Corporation the two are R$1.05 per share apart. That gap is exactly why we show both numbers side by side.
How much is United Therapeutics Corporation worth?
The market values United Therapeutics Corporation at about R$113B (market capitalisation, as of Sep 29, 2026). Per share that is R$142.05; our models calculate a fair value of R$141.00 per share.
What do the bullish and bearish scenarios say about U2TH34?
Our models span a range for United Therapeutics Corporation: cautious scenario R$88.85, base R$141.00, optimistic R$222.82 per share (as of Sep 29, 2026, price R$142.05). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is U2TH34 from its 52-week high?
United Therapeutics Corporation trades at R$142.05, about 8% below its 52-week high of R$153.67 and 25% above the low of R$113.19 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of R$141.00 is for.
Which stocks are comparable to United Therapeutics Corporation?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is United Therapeutics Corporation stock attractive at the current price?
The data as of Sep 29, 2026: price R$142.05, calculated fair value R$141.00 (−1%), Quality Score 73/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of U2TH34 calculated?
We run United Therapeutics Corporation through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of R$141.00, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. United Therapeutics Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of United Therapeutics Corporation (U2TH34)?
The closing price on Oct 2, 2026 was R$142.05. Our model-based fair value is R$141.00, about −1% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with United Therapeutics Corporation right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (R$88.85 to R$222.82) leaves room in how you read the outcome.

Key figures of United Therapeutics Corporation

How large is the market capitalisation of United Therapeutics Corporation (U2TH34)?
The market capitalisation of United Therapeutics Corporation is R$113B (≈ $21.6B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/E ratio of United Therapeutics Corporation (U2TH34)?
The price-to-earnings ratio of United Therapeutics Corporation is 20.3. Price to earnings: how many years of current profit you pay for the stock. A P/E of 10 means ten years of profit.
What is the P/S ratio of United Therapeutics Corporation (U2TH34)?
The price-to-sales ratio of United Therapeutics Corporation is 8.50 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of United Therapeutics Corporation (U2TH34)?
Earnings per share at United Therapeutics Corporation are R$7.01 (price ÷ EPS = P/E 20.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of United Therapeutics Corporation (U2TH34)?
The net margin of United Therapeutics Corporation is 41.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of United Therapeutics Corporation (U2TH34)?
The return on equity (ROE) of United Therapeutics Corporation is 20.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of United Therapeutics Corporation (U2TH34)?
On an EBIT basis the return on assets of United Therapeutics Corporation is 16.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of United Therapeutics Corporation (U2TH34)?
The operating margin of United Therapeutics Corporation is 41.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at United Therapeutics Corporation (U2TH34)?
Revenue at United Therapeutics Corporation is growing −1.6% versus a year earlier (3y avg +18.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at United Therapeutics Corporation (U2TH34)?
Earnings per share at United Therapeutics Corporation are growing −12.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does United Therapeutics Corporation (U2TH34) generate?
The free cash flow of United Therapeutics Corporation is $1.0B (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Continue in the live analysis

Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.

Open the live analysis →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.